☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Celltrion
Celltrion’s SteQeyma (Biosimilar, Stelara) Receives the EC’s Approval to Treat Various Chronic Inflammatory Diseases
August 26, 2024
Celltrion’s Steqeyma (Biosimilar, Stelara) Receives the Health Canada’s Approval to Treat Various Chronic Inflammatory Conditions
August 2, 2024
The EC Grants Approval to Celltrion’s Omlyclo (Biosimilar, Xolair)
May 27, 2024
Celltrion’s CT-P39 (biosimilar, omalizumab) Receives the CHMP’s Recommendation for Marketing Authorization to Treat Multiple Indic...
March 25, 2024
Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)
March 11, 2024
Insights+ Key Biosimilars Events of February 2024
March 4, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.